Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].